Fluvoxamine for Acute COVID-19 Infection: Weak Hypothesis, Predictable Failure
Am J Ther
.
2022 May-Jun;29(3):e342-e343.
doi: 10.1097/MJT.0000000000001502.
Epub 2022 Mar 29.
Author
Peter Manu
1
Affiliation
1
Department of Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY.
PMID:
35383592
DOI:
10.1097/MJT.0000000000001502
No abstract available
Publication types
Editorial
MeSH terms
COVID-19 Drug Treatment*
Fluvoxamine / therapeutic use
Humans
SARS-CoV-2
Selective Serotonin Reuptake Inhibitors
Substances
Serotonin Uptake Inhibitors
Fluvoxamine